Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/306% above fair value
$1.77−0.05 (-3.01%)
Close on Nov 18, 2026Market cap $271.84MP/E –Yield –
Editas Medicine shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Editas Medicine's shares outstanding was 119M at Jun 30, 2026. For fiscal 2025 it was 89M, up 7.8% from the year before. Over ten years it grew 42.5% a year on average. The highest annual figure on record is 89M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 89M | +7.8% |
| FY2024 | Dec 31, 2024 | 82M | +8.4% |
| FY2023 | Dec 31, 2023 | 76M | +10.6% |
| FY2022 | Dec 31, 2022 | 69M | +1.5% |
| FY2021 | Dec 31, 2021 | 68M | +15.4% |
| FY2020 | Dec 31, 2020 | 59M | +17.3% |
| FY2019 | Dec 31, 2019 | 50M | +6.1% |
| FY2018 | Dec 31, 2018 | 47M | +16.8% |
| FY2017 | Dec 31, 2017 | 40M | +25.2% |
| FY2016 | Dec 31, 2016 | 32M | +1155.2% |
| FY2015 | Dec 31, 2015 | 3M | +128.6% |
| FY2014 | Dec 31, 2014 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 119M | +41.3% |
| Q1 FY2026 | Mar 31, 2026 | 98M | +17.8% |
| Q4 FY2025 | Dec 31, 2025 | 97M | +17.8% |
| Q3 FY2025 | Sep 30, 2025 | 90M | +9.2% |
| Q2 FY2025 | Jun 30, 2025 | 84M | +2.6% |
| Q1 FY2025 | Mar 31, 2025 | 83M | +1.4% |
| Q4 FY2024 | Dec 31, 2024 | 83M | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | 82M | +1.0% |
| Q2 FY2024 | Jun 30, 2024 | 82M | +15.3% |
| Q1 FY2024 | Mar 31, 2024 | 82M | +18.9% |
| Q4 FY2023 | Dec 31, 2023 | 82M | +18.9% |
| Q3 FY2023 | Sep 30, 2023 | 82M | +18.8% |
| Q2 FY2023 | Jun 30, 2023 | 71M | +4.0% |
| Q1 FY2023 | Mar 31, 2023 | 69M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | 69M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | 69M | +0.8% |
| Q2 FY2022 | Jun 30, 2022 | 69M | +1.1% |
| Q1 FY2022 | Mar 31, 2022 | 68M | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | 68M | +9.7% |
| Q3 FY2021 | Sep 30, 2021 | 68M | +8.8% |
| Q2 FY2021 | Jun 30, 2021 | 68M | +22.6% |
| Q1 FY2021 | Mar 31, 2021 | 66M | +20.9% |
| Q4 FY2020 | Dec 31, 2020 | 62M | +19.4% |
| Q3 FY2020 | Sep 30, 2020 | 63M | +25.8% |
| Q2 FY2020 | Jun 30, 2020 | 55M | +12.8% |
| Q1 FY2020 | Mar 31, 2020 | 55M | +11.8% |
| Q4 FY2019 | Dec 31, 2019 | 52M | +8.7% |
| Q3 FY2019 | Sep 30, 2019 | 50M | +5.1% |
| Q2 FY2019 | Jun 30, 2019 | 49M | +4.5% |
| Q1 FY2019 | Mar 31, 2019 | 49M | +6.2% |
| Q4 FY2018 | Dec 31, 2018 | 48M | +12.7% |
| Q3 FY2018 | Sep 30, 2018 | 47M | +14.8% |
| Q2 FY2018 | Jun 30, 2018 | 47M | +15.0% |
| Q1 FY2018 | Mar 31, 2018 | 46M | +26.1% |
| Q4 FY2017 | Dec 31, 2017 | 43M | +19.2% |
| Q3 FY2017 | Sep 30, 2017 | 41M | +16.3% |
| Q2 FY2017 | Jun 30, 2017 | 41M | – |
| Q1 FY2017 | Mar 31, 2017 | 36M | – |
| Q4 FY2016 | Dec 31, 2016 | 36M | – |
| Q3 FY2016 | Sep 30, 2016 | 36M | – |
See a number that looks wrong?